.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,089,969

« Back to Dashboard

Claims for Patent: 4,089,969

Title: 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
Abstract:Novel 5-aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid compounds represented by the formula ##STR1## and the pharmaceutically acceptable, non-toxic esters and salts thereof, wherein R is hydrogen or a lower alkyl group containing from 1 to 4 carbon atoms and R.sup.1 is hydrogen, a lower alkyl group having from 1 to 4 carbon atoms, a lower alkoxy group of 1 to 4 carbon atoms, chloro, fluoro or bromo, the R.sup.1 substitution being at the ortho, meta or para positions of the aroyl group and process for the production of such compounds; 5-p-toluoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid is representative of the class. These compounds, as the racemic mixture or the (1)-isomer, are useful as anti-inflammatory, analgesic and antipyretic agents and as smooth muscle relaxants.
Inventor(s): Muchowski; Joseph M. (Mexico City, MX), Kluge; Arthur F. (Los Altos, CA)
Assignee: Syntex (U.S.A.) Inc. (Palo Alto, CA)
Application Number:05/771,286
Patent Claims: 1. A compound selected from the group of those represented by the formula: ##STR8## and the pharmaceutically acceptable, non-toxic alkyl esters having from one to 12 carbon atoms and salts thereof, wherein R represents hydrogen or a lower alkyl group having from 1 to 4 carbon atoms and R.sup.1 represents hydrogen, a lower alkyl group having from 1 to 4 carbon atoms, a lower alkoxy group having from 1 to 4 carbon atoms, chloro, fluoro or bromo, the R.sup.1 substitution being at the ortho, meta or para positions of the aroyl group.

2. A compound of claim 1 wherein R is hydrogen.

3. A compound of claim 1 wherein R is methyl.

4. A carboxylic acid compound of claim 2 wherein R.sup.1 is hydrogen, 5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid.

5. An isopropyl ester of the compound of claim 4, isopropyl 5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylate.

6. A carboxylic acid compound of claim 2 wherein R.sub.1 is o-methyl, 5-o-toluoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid.

7. An isopropyl ester of the compound of claim 6, isopropyl 5-o-toluoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylate.

8. A carboxylic acid compound of claim 2 wherein R.sup.1 is m-methyl, 5-m-toluoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid.

9. An isopropyl ester of the compound of claim 8, isopropyl 5-m-toluoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylate.

10. A carboxylic acid compound of claim 2 wherein R.sup.1 is p-methyl, 5-p-toluoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid.

11. An isopropyl ester of the compound of claim 10, isopropyl 5-p-toluoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylate.

12. A carboxylic acid compound of claim 2 wherein R.sup.1 is p-methoxy, 5-p-methoxybenzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid.

13. An isopropyl ester of the compound of claim 12, isopropyl 5-p-methoxybenzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylate.

14. A carboxylic acid compound of claim 2 wherein R.sup.1 is o-chloro, 5-o-chlorobenzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid.

15. An isopropyl ester of the compound of claim 14, isopropyl 5-o-chlorobenzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylate.

16. A carboxylic acid compound of claim 2 wherein R.sup.1 is m-chloro, 5-m-chlorobenzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid.

17. An isopropyl ester of the compound of claim 16, isopropyl 5-m-chlorobenzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylate.

18. A carboxylic acid compound of claim 2 wherein R.sup.1 is p-chloro, 5-p-chlorobenzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid.

19. An isopropyl ester of the compound of claim 18, isopropyl 5-p-chlorobenzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylate.

20. A carboxylic acid compound of claim 2 wherein R.sup.1 is p-fluoro, 5-p-fluorobenzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid.

21. An isopropyl ester of the compound of claim 20, isopropyl 5-p-fluorobenzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylate.

22. A carboxylic acid compound of claim 2 wherein R.sup.1 is o-fluoro, 5-o-fluorobenzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid.

23. An isopropyl ester of the compound of claim 22, isopropyl 5-o-fluorobenzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylate.

24. A carboxylic acid compound of claim 3 wherein R.sup.1 is p-fluoro, 5-p-fluorobenzoyl-1,2-dihydro-6-methyl-3H-pyrrolo[1,2-a]pyrrole-1-carboxyl ic acid.

25. A sodium, potassium or calcium salt of the compounds according to Formula (A) of claim 1.

26. A sodium salt compound of claim 25 wherein R and R.sup.1 are both hydrogen, sodium 5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylate.

27. A compound of claim 25 wherein R is methyl and R.sup.1 is p-fluoro, sodium-5-p-fluorobenzoyl-1,2-dihydro-6-methyl-3H-pyrrolo[1,2-a]pyrrole-1-c arboxylate.

28. An (l)-acid isomer of Formula (A) of claim 1.

29. The compound of claim 28 wherein R and R.sup.1 are both hydrogen, (l)-5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid.

30. The compound of claim 28 wherein R is methyl and R.sup.1 is p-fluoro, (l)-5-p-fluorobenzoyl-1,2-dihydro-6-methyl-3H-pyrrolo[1,2-a]pyrrole-1-carb oxylic acid.

31. A sodium, potassium or calcium salt of an (l)-acid isomer of Formula (A) of claim 1.

32. The sodium salt compound of claim 31 wherein R and R.sup.1 are both hydrogen, sodium (l)-5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylate.

33. The compound of claim 31 wherein R is methyl and R.sup.1 is p-fluoro, sodium (l)-5-benzoyl-1,2-dihydro-6-methyl-3H-pyrrolo[1,2-a]pyrrole-1-carboxylate.

34. A dicyclohexylamine salt of the compound of claim 6, dicyclohexylamine salt of 5-o-toluoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid.

35. A dicyclohexylamine salt of the compound of claim 14, dicyclohexylamine salt of 5-o-chlorobenzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid.

36. A carboxylic acid compound of claim 2 wherein R.sup.1 is p-ethoxy, 5-p-ethoxybenzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid.

37. An isopropyl ester of the compound of claim 36, isopropyl 5-p-ethoxybenzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylate.

38. A composition for treating inflammation, pain or pyrexia in mammals consisting essentially of a pharmaceutically acceptable non-toxic excipient and a therapeutically effective amount of the racemic mixture or the (l)-isomer of a compound represented by the formula: ##STR9## and the pharmaceutically acceptable, non-toxic alkyl esters having from one to 12 carbon atoms and salts thereof, wherein R is hydrogen or a lower alkyl group having from 1 to 4 carbon atoms and R.sup.1 represents hydrogen, a lower alkyl group having from 1 to 4 carbon atoms, a lower alkoxy group having from 1 to 4 carbon atoms, chloro, fluoro or bromo, the R.sup.1 substitution being at the ortho, meta, or para positions of the aroyl group.

39. A method of treating inflammation, pain or pyrexia in mammals which comprises administering to a mammal suffering therefrom a therapeutically effective amount of the racemic mixture or the (l)-isomer of a compound represented by the formula: ##STR10## and the pharmaceutically acceptable, non-toxic alkyl esters having from one to 12 carbon atoms and salts thereof, wherein R is hydrogen or a lower alkyl group having from 1 to 4 carbon atoms, and R.sup.1 represents hydrogen, a lower alkyl group having from 1 to 4 carbon atoms, a lower alkoxy group having from 1 to 4 carbon atoms, chloro, fluoro or bromo, the R.sup.1 substitution being at the ortho, meta, or para positions of the aroyl group.

40. A composition for administration to a pregnant mammal to delay onset of parturition consisting essentially of a pharmaceutically acceptable non-toxic excipient and a therapeutically effective amount of the racemic mixture or the (l)-isomer of a compound represented by the formula: ##STR11## and the pharmaceutically acceptable, non-toxic alkyl esters having from one to 12 carbon atoms and salts thereof, wherein R is hydrogen or a lower alkyl group having from 1 to 4 carbon atoms and R.sup.1 represents hydrogen, a lower alkyl group having from 1 to 4 carbon atoms, a lower alkoxy group having from 1 to 4 carbon atoms, chloro, fluoro or bromo, the R.sup.1 substitution being at the ortho, meta, or para positions of the aroyl group.

41. A method comprising administering to a pregnant mammal to delay the onset of parturition a therapeutically effective amount of the racemic mixture or the (l)-isomer of a compound selected from the group of compounds represented by the formula: ##STR12## and the pharmaceutically acceptable, non-toxic alkyl esters having from one to 12 carbon atoms and salts thereof, wherein R is hydrogen or a lower alkyl group having from 1 to 4 carbon atoms and R.sup.1 represents hydrogen, a lower alkyl group having from 1 to 4 carbon atoms, a lower alkoxy group having from 1 to 4 carbon atoms, chloro, fluoro or bromo, the R.sup.1 substitution being at the ortho, meta, or para positions of the aroyl group.

42. The method of claim 41 wherein said pregnant mammal is a woman who is not suffering from inflammation, pyrexia, or pain.

43. The method of claim 42 wherein said pregnant woman has had a previous spontaneous abortion, miscarriage or premature delivery, which occurred prior to the time for normal parturition at or about full term.

44. The method of claim 41 wherein said pregnant mammal is a woman who is not suffering from inflammation, pyrexia or nonparturition-causing pain but who is experiencing uterine muscle contractions, said compound being administered in a therapeutically effective amount adapted to reduce the intensity or duration of the uterine muscle contractions, stop the uterine muscle contractions altogether, whereby termination of the pregnancy is postponed from the time it otherwise would have happened.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc